Topical calcineurin inhibitors in eczema and cancer association: A cohort study

References

• Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin Exp Dermatol. 2010;35:12–15.
   PubMed Web of Science ®Google Scholar
• Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol. 2003;21:109–15.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. 2006. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm. Accessed June 21, 2014.
   Google Scholar
• Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43:1956–63.
   PubMed Web of Science ®Google Scholar
• Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808–16.
   PubMed Web of Science ®Google Scholar
• Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123:1111–16.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology (Basel). 2009;219:7–21.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151:594–9.
   PubMed Web of Science ®Google Scholar
• Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165:465–73.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163–78.
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CE, Fernandez-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;153:1036–43.
   Web of Science ®Google Scholar
• Hagstromer L, Ye W, Nyren O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141:1123–7.
   PubMedGoogle Scholar
• Jensen AO, Svaerke C, Kormendine Farkas D, et al. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012;13:29–36.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44–7.
   Google Scholar
• Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–96.
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ. 2005;172:1179–80.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–9.
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs) [abstract]. Pharmacoepidemiol Drug Saf. 2010;19:S12. (Abstract 28).
   Google Scholar
• Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors [abstract]. J Am Acad Dermatol. 2011;64:AB3. (Abstract P203).
   Google Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–48.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009;48:348–55.
   PubMed Web of Science ®Google Scholar
• Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160:665–9.
   PubMed Web of Science ®Google Scholar
• Olson KA, West K, McCarthy PL. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant patients with cutaneous graft-versus-host disease. Pharmacother. 2014;34:e60–4.
   Google Scholar
• Niwa Y, Nasr I. Are we starting to induce skin cancer in order to avoid topical steroids? J Eur Acad Dermatol Venereol. 2005;19:387–9.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Remitz A, Kyllonen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3:381–8.
   PubMedGoogle Scholar
• Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29–35.
   PubMed Web of Science ®Google Scholar
• Kalthoff FS, Winiski A, Fichtinger P, et al. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro. Int Arch Allergy Immunol. 2007;142:255–64.
   PubMed Web of Science ®Google Scholar
• Paller A, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810–22.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2003;4:222–30.
   Web of Science ®Google Scholar
• Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002;27:555–61.
   PubMed Web of Science ®Google Scholar
• Boyle TJ, Coles RE, Kizilbash AM, et al. Effects of cyclosporine on human B-cell lymphoma development in vivo. Surg Oncol. 1992;1:79–86.
   PubMedGoogle Scholar
• Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer. 2006;6:7.
   PubMed Web of Science ®Google Scholar
• Almeida S, Domingues A, Rodrigues L, et al. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol Dis. 2004;17:435–44.
   PubMed Web of Science ®Google Scholar
• Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol. 2003;5:28–37.
   PubMed Web of Science ®Google Scholar
• Wojcik I, Szybka M, Golanska E, et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma. 2005;52:318–24.
   PubMed Web of Science ®Google Scholar
• Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68:6803–9.
   PubMed Web of Science ®Google Scholar